Activation of the Renal GLP-1R Leads to Expression of in the Renal Vascular Tree

Overview

Journal Endocrinol Diabetes Metab

Specialty Endocrinology

Date 2021 Jul 19

PMID 34277961

Citations 4

Authors

Katrine Dahl Bjornholm

Maria Elm Ougaard

Gry Freja Skovsted

Lotte Bjerre Knudsen

Charles Pyke

Affiliations

Soon will be listed here.

Abstract

The GLP-1 receptor (GLP-1R) in the kidney is expressed exclusively in vascular smooth muscle cells in arteries and arterioles. Downstream effects of the activation of the renal vascular GLP-1R are elusive but may involve regulation of the renin-angiotensin-aldosterone system (RAAS). The expression of in the mouse renal vasculature was investigated by in situ hybridization after a single subcutaneous dose of liraglutide, semaglutide and after repeated injections of liraglutide. Single and repeated exposure to GLP-1R agonists induced expression of in the renal vascular smooth muscle cell compartment compared with vehicle injected controls ( < .0001) for both semaglutide and liraglutide. The present data show a robust induction of expression in the vascular smooth muscle cells of the kidney after single and repeated GLP-1R activation and this renin recruitment may be involved in the effects of GLP-1R agonist treatment on kidney disease.

Citing Articles

Glucagon-like peptide-1 receptor: mechanisms and advances in therapy.

Zheng Z, Zong Y, Ma Y, Tian Y, Pang Y, Zhang C Signal Transduct Target Ther. 2024; 9(1):234.

PMID: 39289339 PMC: 11408715. DOI: 10.1038/s41392-024-01931-z.

Semaglutide treatment attenuates vessel remodelling in ApoE-/- mice following vascular injury and blood flow perturbation.

Jensen D, Skovsted G, Bonde M, Bentzon J, Rolin B, Franck G Atheroscler Plus. 2023; 49:32-41.

PMID: 36644202 PMC: 9833261. DOI: 10.1016/j.athplu.2022.05.004.

Nephroprotective Effects of Semaglutide as Mono- and Combination Treatment with Lisinopril in a Mouse Model of Hypertension-Accelerated Diabetic Kidney Disease.

Dalboge L, Christensen M, Madsen M, Secher T, Endlich N, Drenic V Biomedicines. 2022; 10(7).

PMID: 35884965 PMC: 9313388. DOI: 10.3390/biomedicines10071661.

Renoprotective Effects of Incretin-Based Therapy in Diabetes Mellitus.

Yaribeygi H, Atkin S, Montecucco F, Jamialahmadi T, Sahebkar A Biomed Res Int. 2021; 2021:8163153.

PMID: 34471642 PMC: 8405289. DOI: 10.1155/2021/8163153.

References

Sedman T, Heinla K, Vasar E, Volke V . Liraglutide Treatment May Affect Renin and Aldosterone Release. Horm Metab Res. 2016; 49(1):5-9. DOI: 10.1055/s-0042-109065. View

Gomez R, Sequeira-Lopez M . Renin cells in homeostasis, regeneration and immune defence mechanisms. Nat Rev Nephrol. 2018; 14(4):231-245. PMC: 5854538. DOI: 10.1038/nrneph.2017.186. View

Marso S, Bain S, Consoli A, Eliaschewitz F, Jodar E, Leiter L . Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016; 375(19):1834-1844. DOI: 10.1056/NEJMoa1607141. View

Asmar A, Simonsen L, Asmar M, Madsbad S, Holst J, Frandsen E . Renal extraction and acute effects of glucagon-like peptide-1 on central and renal hemodynamics in healthy men. Am J Physiol Endocrinol Metab. 2015; 308(8):E641-9. DOI: 10.1152/ajpendo.00429.2014. View

Ougaard M, Jensen H, Thuen I, Petersen E, Kvist P . Inhibitors of the renin-angiotensin system ameliorates clinical and pathological aspects of experimentally induced nephrotoxic serum nephritis. Ren Fail. 2018; 40(1):640-648. PMC: 6225365. DOI: 10.1080/0886022X.2018.1533867. View

Sequeira-Lopez M, Nagalakshmi V, Li M, Sigmund C, Gomez R . Vascular versus tubular renin: role in kidney development. Am J Physiol Regul Integr Comp Physiol. 2015; 309(6):R650-7. PMC: 4591368. DOI: 10.1152/ajpregu.00313.2015. View

Yu M, Moreno C, Hoagland K, Dahly A, Ditter K, Mistry M . Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive rats. J Hypertens. 2003; 21(6):1125-35. DOI: 10.1097/00004872-200306000-00012. View

Fraga-Silva R, Costa-Fraga F, Murca T, Moraes P, Martins Lima A, Lautner R . Angiotensin-converting enzyme 2 activation improves endothelial function. Hypertension. 2013; 61(6):1233-8. PMC: 3733257. DOI: 10.1161/HYPERTENSIONAHA.111.00627. View

Kim M, Platt M, Shibasaki T, Quaggin S, Backx P, Seino S . GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure. Nat Med. 2013; 19(5):567-75. DOI: 10.1038/nm.3128. View

10.

Chen Y, Lee K, Ni Z, He J . Diabetic Kidney Disease: Challenges, Advances, and Opportunities. Kidney Dis (Basel). 2020; 6(4):215-225. PMC: 7445658. DOI: 10.1159/000506634. View

11.

Bjornholm K, Povlsen G, Ougaard M, Pyke C, Rakipovski G, Tveden-Nyborg P . Decreased expression of the GLP-1 receptor after segmental artery injury in mice. J Endocrinol. 2021; 248(3):289-301. DOI: 10.1530/JOE-20-0608. View

12.

Keeton T, Campbell W . The pharmacologic alteration of renin release. Pharmacol Rev. 1980; 32(2):81-227. View

13.

Kaschina E, Namsolleck P, Unger T . AT2 receptors in cardiovascular and renal diseases. Pharmacol Res. 2017; 125(Pt A):39-47. DOI: 10.1016/j.phrs.2017.07.008. View

14.

Everett A, Carey R, Chevalier R, Peach M, Gomez R . Renin release and gene expression in intact rat kidney microvessels and single cells. J Clin Invest. 1990; 86(1):169-75. PMC: 296704. DOI: 10.1172/JCI114680. View

15.

Ougaard M, Sembach F, Jensen H, Pyke C, Knudsen L, Kvist P . Liraglutide Improves the Kidney Function in a Murine Model of Chronic Kidney Disease. Nephron. 2020; 144(11):595-606. DOI: 10.1159/000509418. View

16.

Gomez R, Chevalier R, Everett A, Elwood J, Peach M, Lynch K . Recruitment of renin gene-expressing cells in adult rat kidneys. Am J Physiol. 1990; 259(4 Pt 2):F660-5. DOI: 10.1152/ajprenal.1990.259.4.F660. View

17.

Chevalier R, Everett A, Gomez R . Decreased perfusion pressure modulates renin and ANG II type 1 receptor gene expression in the rat kidney. Am J Physiol. 1993; 264(4 Pt 2):R696-702. DOI: 10.1152/ajpregu.1993.264.4.R696. View

18.

Skov J, Dejgaard A, Frokiaer J, Holst J, Jonassen T, Rittig S . Glucagon-like peptide-1 (GLP-1): effect on kidney hemodynamics and renin-angiotensin-aldosterone system in healthy men. J Clin Endocrinol Metab. 2013; 98(4):E664-71. DOI: 10.1210/jc.2012-3855. View

19.

Skov J, Pedersen M, Holst J, Madsen B, Goetze J, Rittig S . Short-term effects of liraglutide on kidney function and vasoactive hormones in type 2 diabetes: a randomized clinical trial. Diabetes Obes Metab. 2016; 18(6):581-9. DOI: 10.1111/dom.12651. View

20.

Asmar A, Simonsen L, Asmar M, Madsbad S, Holst J, Frandsen E . Glucagon-like peptide-1 does not have acute effects on central or renal hemodynamics in patients with type 2 diabetes without nephropathy. Am J Physiol Endocrinol Metab. 2016; 310(9):E744-53. DOI: 10.1152/ajpendo.00518.2015. View